Core Viewpoint - Maase Inc. has successfully completed the acquisition of 100% equity interests in Carve Group Ltd, enhancing its position in the healthcare and wellness sector through strategic integration of traditional Chinese medicine resources and biotechnology [1][2][5] Group 1: Acquisition Details - The acquisition was finalized on August 27, 2025, with MAAS acquiring all equity interests from Golden Brighter Limited, WJ Management Company Limited, and Union Chief Limited [2] - As part of the transaction, MAAS issued 195,894,609 Class A ordinary shares at an issue price of US$1.50 per share, totaling approximately US$293.84 million [2] - The Sellers now hold approximately 88.32% of the total issued share capital and 22.22% of the total voting power in MAAS, with a five-year lock-up period for their shares [2] Group 2: Subsidiaries and Resources - Carve Group's subsidiary, Zhongshen Resources Development, holds land use rights for 111 mu of premium forest land in Liaoning Province, featuring over 19,000 wild-grown ginseng roots aged over 40 years [3] - Glyken Bird Nest Technology operates a biotechnology factory in the Guangxi Free Trade Zone, with an annual production capacity of 10 tons of bird's nest peptides and a product portfolio that includes anti-aging and functional food/beverages [4] Group 3: Strategic Intent - MAAS aims to leverage the unique medicinal resources from Zhongshen and the biotechnology capabilities of Glyken to modernize traditional wellness products, establishing a competitive health product ecosystem [5] - The company is focused on enhancing the quality of life through intelligent technology and capital investments, targeting high-quality enterprises with global potential in various sectors including healthcare [6]